Beperminogene perplasmid for the treatment of critical limb ischemia.

about

Beperminogene perplasmid for the treatment of critical limb ischemia.

Item

http://www.wikidata.org/entity/Q38246211

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Beperminogene perplasmid for the treatment of critical limb ischemia.

@en

type

Item

label

Beperminogene perplasmid for the treatment of critical limb ischemia.

@en

prefLabel

Beperminogene perplasmid for the treatment of critical limb ischemia.

@en

P1476

Beperminogene perplasmid for the treatment of critical limb ischemia.

@en

P2093

Akihiko Murakami

http://www.w3.org/2001/XMLSchema#string

Hideki Tomioka

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Suda

http://www.w3.org/2001/XMLSchema#string

Ryuichi Morishita

http://www.w3.org/2001/XMLSchema#string

Toshihiro Kaga

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes.

Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.

Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Thromboangiitis obliterans in the 21st century--a new face of disease.

Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.

Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.

P304

1145-1156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2014.955850

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25190335

http://www.w3.org/2001/XMLSchema#string